个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Treatment barriers and clinical outcome of children with medulloblastoma in China: a report from the Chinese Children's Cancer Group (CCCG).

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ ESCI

作者：
Liu Anthony Pak-Yin[1,2] * ; Zhen Zijun[3] * ; Yang Qunying[4] * ; Yuan Xiaojun[5] ; Ma Xiaoli[6] ; Chen Jianliang[7] ; Wang Jingsheng[8] ; Yang Lihua[9] ; Guo Haixia[10] ; Jiang Lian[11] ; Weng Wenjun[12] ; Huang Libin[13] ; Liu Wei[14] ; Wang Jian[4] ; Wu Shaoxiong[15] ; Zeng Jing[16] ; Jiang Mawei[17] ; He Kejun[5] ; Ge Ming[18] ; Cheng Kevin King-Fai[19] ; Ho Wilson Wai-Shing[20,21] ; Li Chunyu[7] ; Yu Lihua[9] ; Zhu Shuai[6] ; Ng Ho-Keung[22] ; Chan Godfrey Chi-Fung[1,2,*2] ; Sun Xiaofei[3,*1] ;
机构： [1]Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. [2]Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong SAR, China. [3]State Key Laboratory of Oncology in South China, Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. [4]State Key Laboratory of Oncology in South China, Department of Neurosurgery, Sun Yat-sen University Cancer Center, Guangzhou, China. [5]Department of Pediatric Hematology and Oncology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. [6]Medical Oncology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China. [7]Department of Paediatrics and Adolescent Medicine, HKU-Shenzhen Hospital, Shenzhen, China. [8]Department of Neurosurgery, Shenzhen Children's Hospital, Shenzhen, China. [9]Pediatric Center of Zhujiang Hospital, Southern Medical University, Guangzhou, China. [10]Department of Pediatrics, Southern Medical University Nanfang Hospital, Guangzhou, China. [11]Department of Pediatrics, Hebei Medical University the Fourth Hospital, Shijiazhuang, Hebei, China. [12]Department of Pediatrics, Sun Yat-sen University Memorial Hospital, Guangzhou, China. [13]Department of Pediatrics, Sun Yat-sen University the First Affiliated Hospital, Guangzhou, China. [14]Department of Hematology and Oncology, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China. [15]State Key Laboratory of Oncology in South China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. [16]State Key Laboratory of Oncology in South China, Department of Pathology, Sun Yat-sen University Cancer Center, GuangzhouChina. [17]Department of Radiation Oncology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. [18]Department of Neurosurgery, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. [19]Department of Neurosurgery, Hong Kong Children's Hospital, Hong Kong SAR, China. [20]Department of Neurosurgery, HKU-Shenzhen Hospital, Shenzhen, China. [21]Department of Neurosurgery, Queen Mary Hospital, Hong Kong SAR, China. [22]Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong SAR, China.
出处：
DOI： 10.1093/noajnl/vdab134

关键词： children | China | collaborative group | medulloblastoma | multidisciplinary

摘要：
Medulloblastoma (MB) is the most common malignant central nervous system tumor of childhood. Management requires interdisciplinary care and is associated with unique challenges in developing regions. Here, we report the characteristics, clinical outcome and treatment barriers for Chinese children with MB based on a multi-institutional cohort from the Chinese Children's Cancer Group (CCCG).Retrospective cohort study among 12 Chinese pediatric oncology units from the CCCG Brain Tumor Workgroup on patients aged <18 years diagnosed with MB from 2016 to 2019.221 patients (male:female = 138:83) were included, 175 (79%) were ≥3 years of age, and 46 (21%) <3 years. 177 patients (80%) were completely staged, among which 50 (28%) had metastasis and 70 (40%) were considered to have high-risk (HR) disease. Gross/near-total resection was achieved in 203 patients (92%). In patients where molecular grouping could be assigned, 19 (16%), 35 (29%), and 65 (54%), respectively had WNT-activated, SHH-activated, and Group 3/4 MB. The median duration between resection and initiation of adjuvant therapy was 36 days. Respective 2-year PFS and OS rates were 76.0 ± 3.0% and 88.0 ± 2.3%. PFS was significantly associated with age, metastatic status and clinical risk grouping. Chemotherapy use during CSI or alkylator choice were not significant predictors for patient outcome.We reported the clinical profiles and outcome from the largest cohort of Chinese children with MB after multi-modal therapy. Strengths and limitations on the local provision of neuro-oncology service are identified.© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

基金：
Molecular studies are funded partly by the Health and Medical Research Fund (HMRF), Food and Health Bureau of the Government of the Hong Kong Special Administrative Region (Ref: 06171666).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院分区：
出版当年[2021]版：
无
最新[2025]版：
大类 | 3 区 医学
小类 | 3 区 临床神经病学 3 区 肿瘤学
JCR分区：
出版当年[2021]版：
无
最新[2024]版：
Q1 CLINICAL NEUROLOGY Q2 ONCOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. [2]Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong SAR, China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. [2]Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong SAR, China. [3]State Key Laboratory of Oncology in South China, Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. [*1]Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, 651 East Dongfeng Road, Guangzhou, China [*2]Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, 102 Pokfulam Road, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
推荐引用方式(GB/T 7714)：
Liu Anthony Pak-Yin,Zhen Zijun,Yang Qunying,et al.Treatment barriers and clinical outcome of children with medulloblastoma in China: a report from the Chinese Children's Cancer Group (CCCG).[J].NEURO-ONCOLOGY ADVANCES.2021,3(1):doi:10.1093/noajnl/vdab134.
APA：
Liu Anthony Pak-Yin,Zhen Zijun,Yang Qunying,Yuan Xiaojun,Ma Xiaoli...&Sun Xiaofei.(2021).Treatment barriers and clinical outcome of children with medulloblastoma in China: a report from the Chinese Children's Cancer Group (CCCG)..NEURO-ONCOLOGY ADVANCES,3,(1)
MLA：
Liu Anthony Pak-Yin,et al."Treatment barriers and clinical outcome of children with medulloblastoma in China: a report from the Chinese Children's Cancer Group (CCCG).".NEURO-ONCOLOGY ADVANCES 3..1(2021)

相关文献

[1]VEP-M在视觉通路病变中的应用价值(附18例报道) [2]智能化舌体(形)测算仪的研制及应用-附1733例患者检测初步分析 [3]阿帕替尼治疗腹腔低度恶性肌纤维母细胞肉瘤1例及文献回顾 [4]肺结节中西医结合全程管理专家共识 [5]早发型胃癌的特点及研究进展 [6]micrornas在口腔扁平苔藓组织中的表达谱分析及3种mirna的血清学表达 [7]基于cesm影像与病理指标预测乳腺癌her-2和ki-67表达的价值 [8]grhl2与雌激素相关性肿瘤发展关系的研究进展 [9]pd-l1与肿瘤相关免疫细胞的表达在口腔鳞状细胞癌发生发展中的作用 [10]CRISPR/Cas9基因编辑技术在肿瘤研究及治疗中的应用

资源点击量：42329 今日访问量：0 总访问量：1365 更新日期：2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号